title: Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.
abstract: BACKGROUND
  Persistent hyperparathyroidism (HPT) is observed in approximately 50% of kidney transplant recipients one year after transplantation. It may result in hypercalcemia, hypophosphatemia, bone demineralization, vascular calcification, lithiasis, and participate in chronic allograft nephropathy. We evaluated the use of the calcimimetic cinacalcet chloride to correct chronic hypercalcemia in posttransplant HPT, in a prospective single-center study.
  
  
  METHODS
  Nine patients with persistent hypercalcemia (>2.6 mmol/L) and stable graft function were treated with cinacalcet (30 mg/day, thereafter adapted to obtain normal serum Ca levels) for six months. Their immunosuppressive schedule included mycophenolate mofetil (MMF), steroids, and cyclosporine A (4), tacrolimus (4), or sirolimus (2).
  
  
  RESULTS
  Serum Ca levels significantly decreased from 2.75+/-0.15 to 2.59+/-0.10, 2.42+/-0.29 and 2.44+/-0.25 mmol/L by one, two, and six months, respectively (P<0.02, Wilcoxon test for paired data, for all the data points). Parathyroid hormone (PTH) serum levels decreased from 171+/-102 to 134+/-63 pg/ml by two months (P<0.05) and stabilized thereafter (148+/-99 pg/ml at six months; NS). No changes in glomerular filtration rate (49.8+/-18.6 and 51.3+/-19 ml/min at initiation and six months, respectively) and no variation in serum concentration of the immunosuppressive drugs were observed. Three patients withdrew the treatment because gastrointestinal intolerance.
  
  
  CONCLUSIONS
  Cinacalcet allows the correction of hypercalcemia with no interference in immunosuppressive treatment or renal function. However, whether the increased intolerance observed was due to the association of cinacalcet chloride with other drugs required in renal transplantation (e.g., MMF) needs to be assessed.
authors.affiliation: Service de Néphrologie, Transplantation et Dialyse Péritonéale, CHU Lapeyronie, Montpellier, France.
authors.forename: Ilan
authors.initials: I
authors.lastname: Szwarc
authors.forename: Angel
authors.initials: A
authors.lastname: Argilés
authors.forename: Valérie
authors.initials: V
authors.lastname: Garrigue
authors.forename: Sylvie
authors.initials: S
authors.lastname: Delmas
authors.forename: Guillaume
authors.initials: G
authors.lastname: Chong
authors.forename: Sébastien
authors.initials: S
authors.lastname: Deleuze
authors.forename: Georges
authors.initials: G
authors.lastname: Mourad
mesh_terms: D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000453:epidemiology; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D011183:Postoperative Complications / Q000188:drug therapy*; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000601:surgery; D012449:Safety
chemical_list: D009281:Naphthalenes; D010281:Parathyroid Hormone; D010710:Phosphates; D002118:Calcium; D000069449:Cinacalcet